BACKGROUND: Diseases caused by Streptococcus pneumoniae have a high impact in young children whose ability to mount antibodies to capsular polysaccharides is impaired. Pneumococcal surface protein A (PspA) is a potential vaccine candidate for this age group. METHODS: We used Western blot analysis and enzyme immunoassay to study human sera of healthy adults from Alabama (n = 20) and from Finland (n = 21), healthy children from Finland (n = 20) and ill children from Finland, those with pneumococcal invasive infection (n = 26) and those with nonpneumococcal invasive infection (n = 26). RESULTS: Human antibodies to PspA exhibited strong cross-reactivity among different pneumococcal strains. The geometric mean titer of IgG antibody to PspA in sera from 21 healthy adults was 4,040, from ten 3-year-old healthy children 1,080 and from ten 2-month-old healthy children 1,650. The geometric mean titer of PspA antibody of acute phase sera of children with invasive pneumococcal disease was 140, significantly (P < 0.001) lower than the respective value, 1,020, for children with infection caused by other bacteria. CONCLUSIONS: We demonstrate for the first time the existence of antibodies to PspA in human sera in health and disease. The findings in ill children suggest that antibodies to PspA might play a role in protection against pneumococcal disease.
BACKGROUND: Diseases caused by Streptococcus pneumoniae have a high impact in young children whose ability to mount antibodies to capsular polysaccharides is impaired. Pneumococcal surface protein A (PspA) is a potential vaccine candidate for this age group. METHODS: We used Western blot analysis and enzyme immunoassay to study human sera of healthy adults from Alabama (n = 20) and from Finland (n = 21), healthy children from Finland (n = 20) and ill children from Finland, those with pneumococcal invasive infection (n = 26) and those with nonpneumococcal invasive infection (n = 26). RESULTS:Human antibodies to PspA exhibited strong cross-reactivity among different pneumococcal strains. The geometric mean titer of IgG antibody to PspA in sera from 21 healthy adults was 4,040, from ten 3-year-old healthy children 1,080 and from ten 2-month-old healthy children 1,650. The geometric mean titer of PspA antibody of acute phase sera of children with invasive pneumococcal disease was 140, significantly (P < 0.001) lower than the respective value, 1,020, for children with infection caused by other bacteria. CONCLUSIONS: We demonstrate for the first time the existence of antibodies to PspA in human sera in health and disease. The findings in ill children suggest that antibodies to PspA might play a role in protection against pneumococcal disease.
Authors: L Baril; J Dietemann; M Essevaz-Roulet; L Béniguel; P Coan; D E Briles; B Guy; G Cozon Journal: Clin Exp Immunol Date: 2006-08 Impact factor: 4.330
Authors: Taj Azarian; Lindsay R Grant; Maria Georgieva; Laura L Hammitt; Raymond Reid; Stephen D Bentley; David Goldblatt; Mathuran Santosham; Robert Weatherholtz; Paula Burbidge; Novalene Goklish; Claudette M Thompson; William P Hanage; Kate L O'Brien; Marc Lipsitch Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: L Baril; D E Briles; P Crozier; J D King; S K Hollingshead; T F Murphy; J B McCormick Journal: Clin Exp Immunol Date: 2004-03 Impact factor: 4.330
Authors: Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard Journal: Clin Vaccine Immunol Date: 2007-11-21
Authors: Reshmi Mukerji; Shaper Mirza; Aoife M Roche; Rebecca W Widener; Christina M Croney; Dong-Kwon Rhee; Jeffrey N Weiser; Alexander J Szalai; David E Briles Journal: J Immunol Date: 2012-10-26 Impact factor: 5.422